[{"id":"3e6558d8-f022-4465-b340-329db64b8a39","acronym":"VBP101","url":"https://clinicaltrials.gov/study/NCT04849910","created_at":"2021-04-19T11:53:06.069Z","updated_at":"2025-02-25T17:01:02.310Z","phase":"Phase 1/2","brief_title":"Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS","source_id_and_acronym":"NCT04849910 - VBP101","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • tremtelectogene empogeditemcel (VOR33)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-03"}]